3 news items
Cogent Biosciences Reports First Quarter 2024 Financial Results
COGT
7 May 24
are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
COGT
26 Feb 24
should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
COGT
22 Feb 24
, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks
- Prev
- 1
- Next